Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

John A. Auchampach PhD

John A. Auchampach PhD


Institution: Medical College of Wisconsin
Department: Pharmacology and Toxicology
Program: Pharmacology

Member of the Cardiovascular Center

Research Experience

  • Adenosine
  • Cardiovascular Diseases
  • Gene Targeting
  • Heart Failure
  • Inflammation
  • Models, Animal
  • Myocardial Infarction
  • Myocardial Reperfusion Injury
  • Receptors, G-Protein-Coupled
  • Receptors, Purinergic P1
  • Signal Transduction
  • Ventricular Remodeling
  • MCW Program / Core Facilities

  • Cardiovascular Center
    Department of Pharmacology Graduate Program
  • Publications

  • Structure-Based Design, Synthesis by Click Chemistry and in Vivo Activity of Highly Selective A3 Adenosine Receptor Agonists. (Tosh DK, Paoletta S, Chen Z, Crane S, Lloyd J, Gao ZG, Gizewski ET, Auchampach JA, Salvemini D, Jacobson KA) Medchemcomm 2015;6:555-563 PMID: 26236460 PMCID: PMC4517612 08/04/2015
  • Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo Efficacy. (Tosh DK, Crane S, Chen Z, Paoletta S, Gao ZG, Gizewski E, Auchampach JA, Salvemini D, Jacobson KA) ACS Med Chem Lett 2015 Jul 9;6(7):804-8 PMID: 26191370 PMCID: PMC4499829 07/21/2015
  • In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists. (Tosh DK, Finley A, Paoletta S, Moss SM, Gao ZG, Gizewski ET, Auchampach JA, Salvemini D, Jacobson KA) J Med Chem 2014 Dec 11;57(23):9901-14 PMID: 25422861 PMCID: PMC4266358 11/26/2014
  • Rap1b in smooth muscle and endothelium is required for maintenance of vascular tone and normal blood pressure. (Lakshmikanthan S, Zieba BJ, Ge ZD, Momotani K, Zheng X, Lund H, Artamonov MV, Maas JE, Szabo A, Zhang DX, Auchampach JA, Mattson DL, Somlyo AV, Chrzanowska-Wodnicka M) Arterioscler Thromb Vasc Biol 2014 Jul;34(7):1486-94 PMID: 24790136 PMCID: PMC4224284 05/03/2014
  • Effect of human 15-lipoxygenase-1 metabolites on vascular function in mouse mesenteric arteries and hearts. (Kriska T, Cepura C, Siangjong L, Wan TC, Auchampach JA, Shaish A, Haratz D, Kumar G, Falck JR, Gauthier KM, Campbell WB) Prostaglandins Other Lipid Mediat 2013 Oct;106:8-15 PMID: 23872364 PMCID: PMC3844054 07/23/2013
  • Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. (Paoletta S, Tosh DK, Finley A, Gizewski ET, Moss SM, Gao ZG, Auchampach JA, Salvemini D, Jacobson KA) J Med Chem 2013 Jul 25;56(14):5949-63 PMID: 23789857 PMCID: PMC3858399 06/25/2013
  • An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering. (Ntantie E, Gonyo P, Lorimer EL, Hauser AD, Schuld N, McAllister D, Kalyanaraman B, Dwinell MB, Auchampach JA, Williams CL) Sci Signal 2013 May 28;6(277):ra39 PMID: 23716716 PMCID: PMC4278376 05/30/2013
  • Characterization by flow cytometry of fluorescent, selective agonist probes of the A(3) adenosine receptor. (Kozma E, Gizewski ET, Tosh DK, Squarcialupi L, Auchampach JA, Jacobson KA) Biochem Pharmacol 2013 Apr 15;85(8):1171-81 PMID: 23376019 PMCID: PMC3604185 02/05/2013
  • Adenosine A1 receptors heterodimerize with β1- and β2-adrenergic receptors creating novel receptor complexes with altered G protein coupling and signaling. (Chandrasekera PC, Wan TC, Gizewski ET, Auchampach JA, Lasley RD) Cell Signal 2013 Apr;25(4):736-42 PMID: 23291003 PMCID: PMC3896953 01/08/2013
  • Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. (Tosh DK, Deflorian F, Phan K, Gao ZG, Wan TC, Gizewski E, Auchampach JA, Jacobson KA) J Med Chem 2012 May 24;55(10):4847-60 PMID: 22559880 PMCID: PMC3371665 05/09/2012
  • Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A3 adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts. (Wan TC, Tosh DK, Du L, Gizewski ET, Jacobson KA, Auchampach JA) BMC Pharmacol 2011;11:11 PMID: 22039965 PMCID: PMC3247180 11/02/2011
  • Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor. (Du L, Gao ZG, Nithipatikom K, Ijzerman AP, Veldhoven JP, Jacobson KA, Gross GJ, Auchampach JA) J Pharmacol Exp Ther 2012 Jan;340(1):210-7 PMID: 22011434 PMCID: PMC3251031 10/21/2011
  • A role for the low-affinity A2B adenosine receptor in regulating superoxide generation by murine neutrophils. (van der Hoeven D, Wan TC, Gizewski ET, Kreckler LM, Maas JE, Van Orman J, Ravid K, Auchampach JA) J Pharmacol Exp Ther 2011 Sep;338(3):1004-12 PMID: 21693629 PMCID: PMC3164346 06/23/2011
  • Characterization of a critical role for CFTR chloride channels in cardioprotection against ischemia/reperfusion injury. (Xiang SY, Ye LL, Duan LL, Liu LH, Ge ZD, Auchampach JA, Gross GJ, Duan DD) Acta Pharmacol Sin 2011 Jun;32(6):824-33 PMID: 21642951 PMCID: PMC3217336 06/07/2011
  • Are we putting too much stock in mice? (Auchampach JA, Maas JE, Wan TC, Figler RA, Gross GJ) J Mol Cell Cardiol 2011 Mar;50(3):584-5 PMID: 21129379 12/07/2010
  • Evidence that the acute phase of ischemic preconditioning does not require signaling by the A 2B adenosine receptor. (Maas JE, Wan TC, Figler RA, Gross GJ, Auchampach JA) J Mol Cell Cardiol 2010 Nov;49(5):886-93 PMID: 20797398 PMCID: PMC2958103 08/28/2010
  • Activation of the A(3) adenosine receptor inhibits fMLP-induced Rac activation in mouse bone marrow neutrophils. (van der Hoeven D, Gizewski ET, Auchampach JA) Biochem Pharmacol 2010 Jun 1;79(11):1667-73 PMID: 20149782 PMCID: PMC2847012 02/13/2010
  • A(3) adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells. (Ge ZD, van der Hoeven D, Maas JE, Wan TC, Auchampach JA) J Mol Cell Cardiol 2010 Aug;49(2):280-6 PMID: 20132822 PMCID: PMC2885516 02/06/2010
  • Isoflurane postconditioning protects against reperfusion injury by preventing mitochondrial permeability transition by an endothelial nitric oxide synthase-dependent mechanism. (Ge ZD, Pravdic D, Bienengraeber M, Pratt PF Jr, Auchampach JA, Gross GJ, Kersten JR, Warltier DC) Anesthesiology 2010 Jan;112(1):73-85 PMID: 19996950 PMCID: PMC4374483 12/10/2009
  • Synthesis and pharmacological characterization of [(125)I]MRS5127, a high affinity, selective agonist radioligand for the A3 adenosine receptor. (Auchampach JA, Gizewski ET, Wan TC, de Castro S, Brown GG Jr, Jacobson KA) Biochem Pharmacol 2010 Apr 1;79(7):967-73 PMID: 19917269 PMCID: PMC2815200 11/18/2009
  • Adenosine suppresses lipopolysaccharide-induced tumor necrosis factor-alpha production by murine macrophages through a protein kinase A- and exchange protein activated by cAMP-independent signaling pathway. (Kreckler LM, Gizewski E, Wan TC, Auchampach JA) J Pharmacol Exp Ther 2009 Dec;331(3):1051-61 PMID: 19749080 PMCID: PMC2784717 09/15/2009
  • Characterization of the A2B adenosine receptor from mouse, rabbit, and dog. (Auchampach JA, Kreckler LM, Wan TC, Maas JE, van der Hoeven D, Gizewski E, Narayanan J, Maas GE) J Pharmacol Exp Ther 2009 Apr;329(1):2-13 PMID: 19141710 PMCID: PMC2670590 01/15/2009
  • Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor. (Liou GI, Auchampach JA, Hillard CJ, Zhu G, Yousufzai B, Mian S, Khan S, Khalifa Y) Invest Ophthalmol Vis Sci 2008 Dec;49(12):5526-31 PMID: 18641283 PMCID: PMC2588644 07/22/2008
  • Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils. (van der Hoeven D, Wan TC, Auchampach JA) Mol Pharmacol 2008 Sep;74(3):685-96 PMID: 18583455 PMCID: PMC2574951 06/28/2008
  • Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. (Melman A, Gao ZG, Kumar D, Wan TC, Gizewski E, Auchampach JA, Jacobson KA) Bioorg Med Chem Lett 2008 May 1;18(9):2813-9 PMID: 18424135 PMCID: PMC2430186 04/22/2008
  • Adenosine receptors and angiogenesis. (Auchampach JA) Circ Res 2007 Nov 26;101(11):1075-7 PMID: 18040023 PMCID: PMC2399891 11/28/2007
  • The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel. (Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, Gross GJ, Kwok WM, Auchampach JA) J Pharmacol Exp Ther 2008 Jan;324(1):234-43 PMID: 17906066 PMCID: PMC2435594 10/02/2007
  • Reperfusion injury: does it exist? (Gross GJ, Auchampach JA) J Mol Cell Cardiol 2007 Jan;42(1):12-8 PMID: 17069848 PMCID: PMC1876792 10/31/2006
  • Improved cardiac function in infarcted mice after treatment with pluripotent embryonic stem cells. (Nelson TJ, Ge ZD, Van Orman J, Barron M, Rudy-Reil D, Hacker TA, Misra R, Duncan SA, Auchampach JA, Lough JW) Anat Rec A Discov Mol Cell Evol Biol 2006 Nov;288(11):1216-24 PMID: 17004246 PMCID: PMC2566533 09/28/2006
  • Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor. (Ge ZD, Peart JN, Kreckler LM, Wan TC, Jacobson MA, Gross GJ, Auchampach JA) J Pharmacol Exp Ther 2006 Dec;319(3):1200-10 PMID: 16985166 09/21/2006
  • Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. (Carrier EJ, Auchampach JA, Hillard CJ) Proc Natl Acad Sci U S A 2006 May 16;103(20):7895-900 PMID: 16672367 PMCID: PMC1472541 05/05/2006
  • Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. (Kreckler LM, Wan TC, Ge ZD, Auchampach JA) J Pharmacol Exp Ther 2006 Apr;317(1):172-80 PMID: 16339914 12/13/2005
  • Extending the cardioprotective window using a novel delta-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway. (Gross ER, Peart JN, Hsu AK, Auchampach JA, Gross GJ) Am J Physiol Heart Circ Physiol 2005 Jun;288(6):H2744-9 PMID: 15653765 01/18/2005
  • Gene dose-dependent atrial arrhythmias, heart block, and brady-cardiomyopathy in mice overexpressing A(3) adenosine receptors. (Fabritz L, Kirchhof P, Fortmüller L, Auchampach JA, Baba HA, Breithardt G, Neumann J, Boknik P, Schmitz W) Cardiovasc Res 2004 Jun 1;62(3):500-8 PMID: 15158142 PMCID: PMC3910327 05/26/2004
  • Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. (Auchampach JA, Jin X, Moore J, Wan TC, Kreckler LM, Ge ZD, Narayanan J, Whalley E, Kiesman W, Ticho B, Smits G, Gross GJ) J Pharmacol Exp Ther 2004 Mar;308(3):846-56 PMID: 14634049 11/25/2003
  • A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs. (Auchampach JA, Ge ZD, Wan TC, Moore J, Gross GJ) Am J Physiol Heart Circ Physiol 2003 Aug;285(2):H607-13 PMID: 12689858 PMCID: PMC3860822 04/12/2003
  • Comparison of cardioprotective efficacy of two thromboxane A2 receptor antagonists. (Ge ZD, Auchampach JA, Piper GM, Gross GJ) J Cardiovasc Pharmacol 2003 Mar;41(3):481-8 PMID: 12605028 02/27/2003
  • Therapeutic receptor targets of ischemic preconditioning. (Fryer RM, Auchampach JA, Gross GJ) Cardiovasc Res 2002 Aug 15;55(3):520-5 PMID: 12160948 PMCID: PMC3864592 08/06/2002
  • Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor. (Black RG Jr, Guo Y, Ge ZD, Murphree SS, Prabhu SD, Jones WK, Bolli R, Auchampach JA) Circ Res 2002 Jul 26;91(2):165-72 PMID: 12142350 PMCID: PMC3682827 07/27/2002
  • Protection of IB-MECA against myocardial stunning in conscious rabbits is not mediated by the A1 adenosine receptor. (Kodani E, Bolli R, Tang XL, Auchampach JA) Basic Res Cardiol 2001 Sep;96(5):487-96 PMID: 11605996 10/19/2001
  • Cyclooxygenase-2 does not mediate late preconditioning induced by activation of adenosine A1 or A3 receptors. (Kodani E, Shinmura K, Xuan YT, Takano H, Auchampach JA, Tang XL, Bolli R) Am J Physiol Heart Circ Physiol 2001 Aug;281(2):H959-68 PMID: 11454603 07/17/2001
  • Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. (Guo Y, Bolli R, Bao W, Wu WJ, Black RG Jr, Murphree SS, Salvatore CA, Jacobson MA, Auchampach JA) J Mol Cell Cardiol 2001 Apr;33(4):825-30 PMID: 11273734 PMCID: PMC4100593 03/29/2001
  • A(1) or A(3) adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms. (Takano H, Bolli R, Black RG Jr, Kodani E, Tang XL, Yang Z, Bhattacharya S, Auchampach JA) Circ Res 2001 Mar 16;88(5):520-8 PMID: 11249876 03/16/2001
  • A(3) adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury. (Jordan JE, Thourani VH, Auchampach JA, Robinson JA, Wang NP, Vinten-Johansen J) Am J Physiol 1999 Nov;277(5 Pt 2):H1895-905 PMID: 10564145 11/24/1999
  • PKC-dependent activation of p44/p42 MAPKs during myocardial ischemia-reperfusion in conscious rabbits. (Ping P, Zhang J, Cao X, Li RC, Kong D, Tang XL, Qiu Y, Manchikalapudi S, Auchampach JA, Black RG, Bolli R) Am J Physiol 1999 May;276(5 Pt 2):H1468-81 PMID: 10330229 05/18/1999
  • Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges. (Auchampach JA, Bolli R) Am J Physiol 1999 Mar;276(3 Pt 2):H1113-6 PMID: 10070100 03/10/1999
  • Effect of the platelet-activating factor antagonist RP 59227 (Tulopafant) on myocardial ischemia/reperfusion injury and neutrophil function. (Auchampach JA, Pieper GM, Cavero I, Gross GJ) Basic Res Cardiol 1998 Oct;93(5):361-71 PMID: 9833148 12/02/1998
  • The structure and function of A1 and A2B adenosine receptors. (Linden J, Auchampach JA, Jin X, Figler RA) Life Sci 1998;62(17-18):1519-24 PMID: 9585129 05/19/1998
  • Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor. (Auchampach JA, Jin X, Wan TC, Caughey GH, Linden J) Mol Pharmacol 1997 Nov;52(5):846-60 PMID: 9351976 11/14/1997
  • Selective activation of A3 adenosine receptors with N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. (Auchampach JA, Rizvi A, Qiu Y, Tang XL, Maldonado C, Teschner S, Bolli R) Circ Res 1997 Jun;80(6):800-9 PMID: 9168782 06/01/1997
  • PD 81,723, an allosteric enhancer of the A1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs. (Mizumura T, Auchampach JA, Linden J, Bruns RF, Gross GJ) Circ Res 1996 Sep;79(3):415-23 PMID: 8781475 09/01/1996
  • Cloning of a canine cDNA homologous to the human transforming growth factor-beta 1-encoding gene. (Manning AM, Auchampach JA, Drong RF, Slightom JL) Gene 1995 Apr 3;155(2):307-8 PMID: 7721110 04/03/1995
  • Attenuation of oxidant-induced lung injury by 21-aminosteroids (lazaroids): correlation with the mRNA expression for E-selectin, P-selectin, ICAM-1, and VCAM-1. (Griffin RL, Krzesicki RF, Fidler SF, Rosenbloom CL, Auchampach JA, Manning AM, Haas JV, Cammarata SK, Chin JE, Richards IM) Environ Health Perspect 1994 Dec;102 Suppl 10:193-200 PMID: 7535686 PMCID: PMC1567004 12/01/1994
  • Cloning, sequence comparison and in vivo expression of the gene encoding rat P-selectin. (Auchampach JA, Oliver MG, Anderson DC, Manning AM) Gene 1994 Aug 5;145(2):251-5 PMID: 7520013 08/05/1994
  • Cardioprotective actions of potassium channel openers. (Auchampach JA, Maruyama M, Gross GJ) Eur Heart J 1994 Aug;15 Suppl C:89-94 PMID: 7995278 08/01/1994
  • The ATP-regulated potassium channel in ischemia-reperfusion injury. (Gross GJ, Yao Z, Pieper GM, Auchampach JA) Ann N Y Acad Sci 1994 Jun 17;723:71-81 PMID: 8030926 06/17/1994
  • Reduction in myocardial infarct size by the new potassium channel opener bimakalim. (Auchampach JA, Gross GJ) J Cardiovasc Pharmacol 1994 Apr;23(4):554-61 PMID: 7516004 04/01/1994
  • In vitro activation of brain protein kinase C by the cannabinoids. (Hillard CJ, Auchampach JA) Biochim Biophys Acta 1994 Jan 13;1220(2):163-70 PMID: 8312360 01/13/1994
  • Anti-ischaemic actions of potassium channel openers in experimental myocardial ischaemia/reperfusion injury in dogs. (Auchampach JA, Gross GJ) Eur Heart J 1993 Jul;14 Suppl B:10-5 PMID: 8370365 07/01/1993
  • Cardioprotective effects of monophosphoryl lipid A, a novel endotoxin analogue, in the dog. (Yao Z, Auchampach JA, Pieper GM, Gross GJ) Cardiovasc Res 1993 May;27(5):832-8 PMID: 8394211 05/01/1993
  • Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs. (Auchampach JA, Gross GJ) Am J Physiol 1993 May;264(5 Pt 2):H1327-36 PMID: 8498546 05/01/1993
  • Relationship of severity of myocardial stunning to ATP dependent potassium channel modulation. (Warltier DC, Auchampach JA, Gross GJ) J Card Surg 1993 Mar;8(2 Suppl):279-83 PMID: 8461517 03/01/1993
  • Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate. (Auchampach JA, Grover GJ, Gross GJ) Cardiovasc Res 1992 Nov;26(11):1054-62 PMID: 1291082 11/01/1992
  • Role of ATP dependent potassium channels in myocardial ischaemia. (Gross GJ, Auchampach JA) Cardiovasc Res 1992 Nov;26(11):1011-6 PMID: 1291076 11/01/1992
  • Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. (Auchampach JA, Maruyama M, Cavero I, Gross GJ) Circulation 1992 Jul;86(1):311-9 PMID: 1301066 07/01/1992
  • Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. (Gross GJ, Auchampach JA) Circ Res 1992 Feb;70(2):223-33 PMID: 1310443 02/01/1992
  • Cardioprotective effects of nicorandil. (Gross GJ, Auchampach JA, Maruyama M, Warltier DC, Pieper GM) J Cardiovasc Pharmacol 1992;20 Suppl 3:S22-8 PMID: 1282172 01/01/1992
  • Nicorandil attenuates myocardial dysfunction associated with transient ischemia by opening ATP-dependent potassium channels. (Auchampach JA, Cavero I, Gross GJ) J Cardiovasc Pharmacol 1992;20(5):765-71 PMID: 1280739 01/01/1992
  • The new K+ channel opener Aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes. (Auchampach JA, Maruyama M, Cavero I, Gross GJ) J Pharmacol Exp Ther 1991 Dec;259(3):961-7 PMID: 1762089 12/01/1991
  • Last update: 09/28/2015